PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid.
Sign Up to like & getrecommendations! Published in 2021 at "Pharmaceutical research"
DOI: 10.1007/s11095-021-03095-9
Abstract: PURPOSE Isoniazid (INH) is prescribed both for the prophylaxis as well as the treatment of tuberculosis. It is primarily metabolized through acetylation by a highly polymorphic enzyme, N-acetyl transferase 2 (NAT2), owing to which significant… read more here.
Keywords: isoniazid; cyp2c19 cyp3a4; study; drug ... See more keywords
Determination of lansoprazole, 5-hydroxylansoprazole, and lansoprazole sulfone in human plasma for CYP2C19 and CYP3A4 phenotyping
Sign Up to like & getrecommendations! Published in 2019 at "Chemical Papers"
DOI: 10.1007/s11696-019-00682-4
Abstract: A simple and sensitive liquid chromatography method with absorbance or mass spectrometry detection was developed and validated for the determination of lansoprazole, lansoprazole sulfone, and 5-hydroxylansorpazole in human serum with omeprazole as an internal standard.… read more here.
Keywords: lansoprazole sulfone; determination lansoprazole; cyp2c19 cyp3a4;
Abstract 3035: Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19 and CYP3A4 in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-3035
Abstract: Background: Adavosertib (AD), a selective WEE1 inhibitor, may alter exposure to compounds metabolized by cytochromes P450 (CYP); this two-period open-label study (NCT03333824) assessed the effect of AD on pharmacokinetics (PK) of probe substrates for CYP1A2… read more here.
Keywords: solid tumors; cyp1a2 cyp2c19; cyp2c19 cyp3a4; substrates cyp1a2 ... See more keywords
Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14050915
Abstract: The antiplatelet agent clopidogrel is listed by the FDA as a strong clinical index inhibitor of cytochrome P450 (CYP) 2C8 and weak clinical inhibitor of CYP2B6. Moreover, clopidogrel is a substrate of—among others—CYP2C19 and CYP3A4.… read more here.
Keywords: interaction; based pharmacokinetic; cyp2c19 cyp3a4; physiologically based ... See more keywords